Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

ClinicalTrials.gov ID: NCT07259317

Public ClinicalTrials.gov record NCT07259317. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Chemotherapy-Naïve Patients With Metastatic Pancreatic Adenocarcinoma (TRIDENT)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic adenocarcinoma (PDAC).

Study identification

NCT ID: NCT07259317
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Corcept Therapeutics; Industry
Enrollment: 80 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 26, 2026
Primary completion: Aug 31, 2027
Completion: Aug 31, 2027
Last update posted: Aug 17, 2026

2026 – 2027

United States locations

U.S. sites: 16
U.S. states: 11
U.S. cities: 16

Facility	City	State	ZIP	Site status
Site 02	Scottsdale	Arizona	85258	Recruiting
Site 04	Los Angeles	California	90025	Recruiting
Site 12	Orange	California	92868	Recruiting
Site 06	Atlanta	Georgia	30322	Recruiting
Site 14	Goshen	Indiana	46526	Recruiting
Site 15	Westwood	Kansas	66205	Recruiting
Site 03	Grand Rapids	Michigan	49503	Recruiting
Site 10	East Brunswick	New Jersey	08816	Recruiting
Site 11	Morristown	New Jersey	07960	Recruiting
Site 08	Albany	New York	12206	Recruiting
Site 05	Lake Success	New York	11042	Withdrawn
Site 07	Shirley	New York	11967	Recruiting
Site 13	Cincinnati	Ohio	45219	Recruiting
Site 09	Nashville	Tennessee	37203	Recruiting
Site 16	Fort Worth	Texas	76104	Recruiting
Site 01	San Antonio	Texas	78229	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07259317, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 17, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07259317 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →